Journal of Experimental & Clinical Cancer Research 2009, 28:115 http://www.jeccr.com/content/28/1/115 bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 2003, 1010:764-770. 21. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, Du L, Wei ML, Wu XT: P53 codon 72 polymorphism and gastric cancer: a meta- analysis of the literature. Int J Cancer 2007, 121:1481-1486. 22. Khayat AS, Lobo Gatti L, Moura Lima E, de Assumpção PP, Nasci- mento Motta FJ, Harada ML, Casartelli C, Marques Payão SL, Cardoso Smith MA, Burbano RR: Polymorphisms of the TP53 codon 72 and WRN codon 1367 in individuals from Northern Brazil with gastric adenocarcinoma. Clin Exp Med 2005, 5:161-168. 23. Munafò MR, Clark TG, Flint J: Assessing publication bias in genetic association studies: evidence from a recent meta- analysis. Psychiatry Res 2004, 129:39-44. 24. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta- analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 25. Rosenthal R: The "file drawer problem" and tolerance for results. Psychol Bull 1979, 86:638-641. 26. Vieira JO, da Silva ID, Higo PE, Nogueira-de-Souza NC, Gebrim LH: Study of p53 codon 72 polymorphism in patients with breast cancer. Eur J Gynaecol Oncol 2008, 29:364-367. 27. Bonafé M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, Franceschi C: Retention of the p53 codon 72 arginine allele is associated with a reduc- tion of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 2003, 9:4860-4864. 28. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y: p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005, 11:7328-7333. 29. Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, Soo KC, Sabapathy K: Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer develop- ment. Cancer Epidemiol Biomarkers Prev 2005, 14:2245-2252. 30. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y: Association of TP53 codon 72 polymorphism and the outcome of adjuvant ther- apy in breast cancer patients. Breast Cancer Res 2007, 9:R34. 31. Hamaguchi M, Nishio M, Toyama T, Sugiura H, Kondo N, Fujii Y, Yamashita H: Possible difference in frequencies of genetic pol- ymorphisms of estrogen receptor alpha, estrogen metabo- lism and P53 genes between estrogen receptor-positive and -negative breast cancers. Jpn J Clin Oncol 2008, 38:734-742. 32. Vannini I, Zoli W, Tesei A, Rosetti M, Sansone P, Storci G, Passardi A, Massa I, Ricci M, Gusolfino D, Fabbri F, Ulivi P, Brigliadori G, Amadori D, Bonafe M: Role of p53 codon 72 arginine allele in cell sur- vival in vitro and in the clinical outcome of patients with advanced breast cancer. Tumour Biol 2008, 29:145-151. 33. Lum SS, Chua HW, Li H, Li WF, Rao N, Wei J, Shao Z, Sabapathy K: MDM2 SNP309 G allele increases risk but the T allele is asso- ciated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 2008, 29:754-761. 34. Kyndi M, Alsner J, Hansen LL, Sørensen FB, Overgaard J: LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. Acta Oncol 2006, 45:602-609. 35. Ogretmen B, Safa AR: Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical char- acterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 1997, 14:499-506. 36. Langerød A, Bukholm IR, Bregård A, Lønning PE, Andersen TI, Rog- num TO, Meling GI, Lothe RA, Børresen-Dale AL: The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Can- cer Epidemiol Biomarkers Prev 2002, 11:1684-1688. 37. Weston A, Godbold JH: Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 1997, 105(Suppl 4):919-926. 38. Papadakis EN, Dokianakis DN, Spandidos DA: p53 codon 72 poly- morphism as a risk factor in the development of breast can- cer. Mol Cell Biol Res Commun 2000, 3:389-392. 39. Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S: Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Can- cer Lett 2004, 210:197-203. 40. Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S, Friedman E: The R72P P53 mutation is asso- ciated with familial breast cancer in Jewish women. Br J Cancer 2005, 92:1144-1148. 41. Damin AP, Frazzon AP, Damin DC, Roehe A, Hermes V, Zettler C, Alexandre CO: Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 2006, 30:523-529. 42. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F: Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of suscepti- bility on breast cancer. BMC Cancer 2008, 8:32. 43. Själander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L: p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996, 17:1313-1316. 44. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS: p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 1997, 6:105-112. 45. Li T, Lu ZM, Guo M, Wu QJ, Chen KN, Xing HP, Mei Q, Ke Y: p53 codon 72 polymorphism (C/G) and the risk of human papil- lomavirus-associated carcinomas in China. Cancer 2002, 95:2571-2576. 46. Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang- Claude J: Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 2002, 12:269-272. 47. Buyru N, Tigli H, Dalay N: P53 codon 72 polymorphism in breast cancer. Oncol Rep 2003, 10:711-714. 48. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K: Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast can- cer. Breast Cancer 2003, 10:307-311. 49. Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N, Gopalkrishna V, Husain SA, Das BC: Polymorphism of the p53 codon 72 Arg/ Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem 2003, 252:117-124. 50. Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Saïd S, Daoud J, Frikha M, Jlidi R, Gargouri A: No evidence of cor- relation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 2003, 1010:764-770. 51. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A: The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 2005, 222:57-65. 52. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ris- timäki A, von Smitten K, Aittomäki K, Heikkilä P, Blomqvist C, Nevan- linna H: Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005, 11:5098-5103. 53. Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM, SEARCH breast cancer study: Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 2007, 9(2):R27. 54. Gochhait S, Bukhari SI, Bairwa N, Vadhera S, Darvishi K, Raish M, Gupta P, Husain SA, Bamezai RN: Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to spo- radic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res 2007, 9:R71. 55. Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A: Polymor- phism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 2007, 173:38-42. 56. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tol- lenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dörk T, Van't Veer LJ, Breast Cancer Association Consortium: Do MDM2 SNP309 and TP53 R72P interact in breast cancer sus- ceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 2007, 67(19):9584-9590. 57. Sprague BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock SJ, Haines JL, Egan KM: Page 8 of 9 (page number not for citation purposes)